Deciphering Mechanisms Underlying Cancer Immunogenicity

This trial is a translational, open-label, multicentric, prospective cohort study of 1100 patients aiming to describe the PD-1 (programmed death) expression in T cells (T lymphocytes) in different solid tumors. The study will be conducted on a population of patients with local and/or metastatic malignant solid tumor and who are followed within a standard of care procedure or clinical trial. Patients with any of the following tumor types may be enrolled in the trial: * Head and neck cancer, * Ovarian cancer, * Cervical cancer, * Pre-invasive CIN III cervical cancer (Cervical Intra-epithelial

Trial Details

NCT ID
NCT03958240
Phase
NA
Sponsor
Institut Claudius Regaud
Status
RECRUITING
Cancer Type
Glioblastoma (GBM) Brain Cancer
Interventions
  • Blood samples, tumor biopsy specimens and ascites samples will be collected.
Locations (sample)
  • Toulouse, France|43.60426,1.44367
  • Toulouse, France|43.60426,1.44367
  • Toulouse, France|43.60426,1.44367

Key Eligibility Criteria

  • Patient with histologically documented local or metastatic solid malignant tumor (head and neck, ovarian, cervical, and other tumor types including…
  • Age ≥ 18 years at the time of study entry
  • Patient followed within a standard of care procedure or clinical trial
  • ECOG Performance status 0-2

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Glioblastoma (GBM) Brain Cancer Trials on Trialify →